Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells

A Pilot Clinical Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cell in the Treatment of Decompensated Alcoholic Cirrhosis

The main purpose of this study is to evaluate the safety and tolerance of umbilical cord mesenchymal stem cells (UCMSCs) in patients with decompensated alcoholic cirrhosis, and to provide dose basis for subsequent clinical study design. We will also explore the possible mechanism of UCMSCs in the treatment of decompensated alcoholic cirrhosis (DAC).

Study Overview

• Status: Recruiting
• Conditions: Alcoholic Cirrhosis
• Intervention / Treatment: Biological: Conventional therapy plus low dose UCMSCs treatment; Biological: Conventional therapy plus medium dose UCMSCs treatment; Biological: Conventional therapy plus high dose UCMSCs treatment

Detailed Description

This study adopted a single-center, single-arm, single-dose combined multiple-dose administration, and dose-escalation clinical trial design to evaluate the safety, tolerability and preliminary effectiveness of UCMSCs in the treatment of patients with decompensated liver cirrhosis. Patients were recruited into three different dose groups, and 12 subjects were enrolled in each group. The subjects of each group will receive 0.5×10^6 cells/kg, 1.0×10^6 cells/kg, and 2.0×10^6 cells/kg respectively. According to the principle of dose escalation, subjects preset to low-dose will receive the administration first. Each group will receive only one corresponding dose for safety and tolerability check. The subjects will be observed for 21 days after the initial dose due to limited proliferation or differentiation potential and relatively low immunogenicity of mesenchymal stem cell products. The safety measures will be discussed by the Data Safety and Monitoring Board (DSMB) to determine whether subjects who have received a single dose will proceed with subsequent injections. Once all subjects in the lower-dose group have completed the initial administration and observed for 21 days. The DSMB will decided whether to proceed with the next-dose group. All subjects will receive routine drug treatment during the study. Primary endpoint: incidence and severity of cell therapy related adverse events from the beginning of treatment to the end of the follow-up. Secondary end point of the study includes: the change in Model For End-Stage Liver Disease (MELD) score of the subjects from baseline, at 1, 3, 6 and 12 months after the last administration; the overall survival rate at the 12th month after the last administration; Changes in liver function compared with baseline at 1, 3, 6 and 12 months after the last administration; changes of child Pugh score compared with baseline at 1, 3, 6 and 12 months after the last administration; and the change of Karnofsky Performance Status Scale (KPS) score from baseline at 1, 3, 6 and 12 months after the last administration.

• Study Type: Interventional
• Enrollment (Anticipated): 36
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Peiwen Lian, PhD; Phone Number: 82708 86 05356691999; Email: lianpeiwen@qq.com
• Study Contact Backup: Name: Jun Cui, MD; Phone Number: 82730 86 05356691999; Email: cuijun89@163.com

Study Locations

• China
  • Shandong
    • Yantai, Shandong, China, 264000
      • Recruiting
      • Yantai Yuhuangding Hospital
      • Contact: Jun Cui, MD; Phone Number: 82730 86 05356691999; Email: cuijun89@163.com
      • Contact: Peiwen Lian, PhD; Phone Number: 82708 86 05356691999; Email: lianpeiwen@.qqcom

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age 18~60 years old;
2. The subject was diagnosed as decompensated alcoholic liver cirrhosis, according to the Guidelines for the Diagnosis and Treatment of Liver Cirrhosis and the Guidelines for the Prevention and Treatment of Alcoholic Liver Disease (2018);
3. The subject was previously diagnosed but treatment is ineffective;
4. Liver function was in child Pugh grade A or MELD score < 12;
5. Intermittent albumin supplementation and diuretic treatment are required;
6. The subject's Albumin level is less than 35g/L, total bilirubin is smaller than 10 times of the upper limit of normal value (hepatocyte hepatitis), or smaller than 15 times of the upper limit of normal value (cholestatic hepatitis or hepatocyte combined with cholestatic hepatitis), prothrombin activity is over 40% (grade II or lower hepatic encephalopathy has been controlled);
7. No history of gastrointestinal hemorrhage in the past month;
8. The subject understand and voluntarily sign the informed consent.

Exclusion Criteria:

1. The subject is allergic physique, with a history of drug or food allergies, especially those who are allergic to umbilical cord mesenchymal stem cells and any components in excipients;
2. The subject suffer acute attack of gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome or infection;
3. The subject suffer systemic infection or severe infection during screening;
4. Abnormal laboratory examinations results, including blood routine: peripheral blood white blood cell count <2.0×10^9/L or >12×10^9/L, hemoglobin (Hb) is less than 70% lower limit of the normal value, platelets <50×10^9/L ; Liver function: ALT or AST> 5 times the upper limit of normal; Renal function: Serum Creatinine (sCr)> 1.5 times the upper limit of normal; in case of abnormality, test shall be repeated;
5. Those who were positive for Hepatitis B surface Antigen (HBsAg) or Hepatitis C virus (HCV) antibody, Human Immunodeficiency Virus (HIV) antibody or syphilis antibody during screening;
6. Subjects suffer from serious, progressive, or uncontrolled diseases of important organs (including cardiovascular system, liver, lung and kidney), and other autoimmune diseases, malignant tumors, or a history of previous tumors, as well as other diseases that researchers believe that they are not suitable to participate in this clinical study.
7. Subject who has received stem cell therapy within 6 months before the screening;
8. Subject who has received biotherapy or participated in other clinical studies within 3 months before screening;
9. Female subjects who are pregnant, lactating, or premenopausal subject who failed to take medically approved non-drug contraceptive measures (such as intrauterine device, condom, female sterilization) during treatment and within 6 months after the treatment; or have a pregnancy plan within 6 months after the end of the study;
10. Male subjects who fail to take medically approved non-drug contraceptive measures (such as male sterilization or condom) during the treatment period and within 6 months after the end of the treatment;
11. Other factors that the researchers believe are not suitable for entering the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: High dose UCMSCs	Biological: Conventional therapy plus high dose UCMSCs treatment; Patients will receive conventional therapy plus high dose UCMSCs treatment (2×10^6 UCMSCs/kg body)
Experimental: Low dose umbilical cord mesenchymal stem cells (UCMSCs)	Biological: Conventional therapy plus low dose UCMSCs treatment; Patients will receive the conventional therapy plus low dose UCMSCs treatment (0.5×10^6 UCMSCs/kg body)
Experimental: Medium dose UCMSCs	Biological: Conventional therapy plus medium dose UCMSCs treatment; Patients will receive conventional therapy plus medium dose UCMSCs treatment (1×10^6 UCMSCs/kg body)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Severity and incidence of adverse events (SIAE) on the 3rd day after the first administration	According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.	The 3rd day after the first administration
1 week SIAE after the first administration	According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.	1 week after the first administration
3 weeks SIAE after the first administration	According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.	3 week after the first administration
3 week SIAE after the the second administration	According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.	3 weeks after the the second administration
1 month SIAE after the last administration	According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.	1 month after the last administration
3 months SIAE after the last administration	According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.	3 months after the last administration
6 months SIAE after the last administration	According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.	6 months after the last administration
12 months SIAE after the last administration	According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.	12 months after the last administration
24 months SIAE after the last administration	According to the evaluation criteria of common adverse events (CTCAE v5.0), any AE occurred in all subjects during the clinical study, including abnormalities in clinical symptoms and vital signs and abnormalities in laboratory examination was observed.	24 months after the last administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Child-Pugh score (effectiveness evaluation index)	The Child-Pugh grading standard is a grading standard commonly used in clinical practice to quantitatively evaluate the liver reserve function of patients with liver cirrhosis. Grading: 5~6 points for Grade A, 7~9 points for Grade B and 10~15 points for grade C; Note: For Primary Biliary Cirrhosis (PBC) or Primary Sclerosing Cholangitis (PSC): total bilirubin (umol/L): 17~68 is 1 point, 68~170 is 1 point, and >170 is 1 point; The Child-Pugh grading standard has been widely recognized by clinicians, and provides a specific clinical reference for the selection of treatment options for patients with liver cirrhosis and has important clinical value.	At baseline, 3, 7 and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6 and 12 months after the last administration.
Survival rate (effectiveness evaluation index)	Overall survival rate of participants in this study.	12 months after the last administration.
Liver function (effectiveness evaluation index)	Indicators: Alanine transaminase (AST), Alanine transaminase (ALT)	Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.
The Model for End-Stage Liver Disease (MELD) score (effectiveness evaluation index)	MELD is a numerical scale, ranging from 6 (less ill) to 40 (gravely ill), used for liver transplant candidates age 12 and older. It gives each person a 'score' (number) based on how urgently he or she needs a liver transplant within the next three months. The number is calculated by a formula using three routine lab test results: MELD score = 3.8×ln[bilirubin (mg/dl)] + 11.2×ln(INR) + 9.6×ln[Scr(mg/dl)] + 6.4×(Cause: Bile or alcoholic 0, other 1) Bilirubin (mg/dl) = Bilirubin (μmol/L)/17.1 Scr(mg/dl) = Scr(μmol/L)/88.4	Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.
KPS score (effectiveness evaluation index)	KPS score is the Karnofsky (Karen, KPS, percentile method) functional status scoring standard. The higher the score, the better the health status, and the more the patient able to tolerate the side effects of treatment, hence a better curative effect. It is generally believed that a Karnofsky score above 80 is independent, which means the patient is able to take care of himself. Karnofsky score between 50 to 70 stands for a semi-independent status, that is, the patient is semi-self-care. A score of 50 means the patients require help from others. Those with a score greater than 80 are in better postoperative state and have a longer survival period. The lower the score, the worse the health status. If the score is less than 60, many effective anti-tumor treatments cannot be implemented.	Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.
Detection of Blood Coagulation Index of PT (effectiveness evaluation index)	To test the blood coagulation index of Prothrombin time (PT);	Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.
Detection of Blood Coagulation Index of APTT (effectiveness evaluation index)	To test the blood coagulation index of activated partial thromboplastin time (APTT);	Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.
Detection of Blood Coagulation Index of TT (effectiveness evaluation index)	To test the blood coagulation index of thrombin time (TT);	Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.
Detection of Blood Coagulation Index of FIB (effectiveness evaluation index)	To test the blood coagulation index of fibrinogen (FIB);	Baseline, 3, 7, and 21 days after the first administration, 21 days after the second administration (if any), and 1, 3, 6, and 12 months after the last administration.

Collaborators and Investigators

• Sponsor: Yantai Yuhuangding Hospital
• Investigators: Principal Investigator: Jun Cui, MD, Yantai Yuhuangding Hospital

Study record dates

Study Major Dates

• Study Start (Actual): June 13, 2022
• Primary Completion (Anticipated): December 25, 2024
• Study Completion (Anticipated): December 25, 2024

Study Registration Dates

• First Submitted: November 19, 2021
• First Submitted That Met QC Criteria: December 9, 2021
• First Posted (Actual): December 13, 2021

Study Record Updates

• Last Update Posted (Actual): March 28, 2023
• Last Update Submitted That Met QC Criteria: March 26, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Chemically-Induced Disorders; Digestive System Diseases; Pathologic Processes; Alcohol-Related Disorders; Substance-Related Disorders; Liver Diseases; Liver Diseases, Alcoholic; Alcohol-Induced Disorders; Fibrosis; Liver Cirrhosis; Liver Cirrhosis, Alcoholic
• Other Study ID Numbers: 2021-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No